Barclays PLC upgraded Charles River Laboratories Intl. Inc (NYSE:CRL) to Equal Weight in a report released today.
- Updated: November 30, 2016
Barclays PLC has upgraded Charles River Laboratories Intl. Inc (NYSE:CRL) to Equal Weight in a statement released on 11/30/2016.
On 2/11/2016, UBS Securities released a statement on Charles River Laboratories Intl. Inc (NYSE:CRL) upped the target price from $75.00 to $76.00 that suggested an upside of 0.07%.
Having a price of $71.56, Charles River Laboratories Intl. Inc (NYSE:CRL) traded 2.07% higher on the day. With the last close down -10.75% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the same period. CRL has recorded a 50-day average of $76.01 and a two hundred day average of $81.84. Trade Volume was down over the average, with 11,698 shares of CRL changing hands under the typical 460,870
Recent Performance Chart
Charles River Laboratories Intl. Inc has price-earnings ratio of 24.68 with a one year low of $65.70 and a one year high of $89.18 and has a total market value of $0.
A total of 15 equity analysts have released a ratings update on CRL. Six equity analysts rating the company a strong buy, three equity analysts rating the company a buy, eight equity analysts rating the company a hold, two equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $85.47.
Brief Synopsis About Charles River Laboratories Intl. Inc (NYSE:CRL)
Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.